MEN1 and Zollinger-Ellison syndrome: Most of these controversies are unique to the management of patients with ZES including those related to control of the acid hypersecretion; controversies related to the diagnosis of ZES; each of the three MEN1/ZES controversies, and controversies related to the non-surgical primary NET ablation for treatment, whereas controversies related to the selection sequence of anti-tumor medical treatments in patients with advanced disease is shared by patients with all malignant pNETs and in many aspects with the management of patients with any advanced NET.